| A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib |
Ongoing |
remibrutinib |
3 |
CLOU064C123 |
King Faisal Specialist Hospital and Research Center (Jeddah) - King Abdulaziz Medical City NG (Jeddah) - King Abdulaziz Medical City NG (Riyadh) |
| An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients with Hereditary Angioedema Type I or II |
Ongoing |
Sebetralstat |
3 |
KVD900-302 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn’s Disease |
Ongoing |
Guselkumab |
3 |
CNTO1959CRD3005 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Specialist Hospital (Dammam), King Saud Medical City (Riyadh), King Abdulaziz Medical City NG (Jeddah) |
| A prospective observational international study of cabozantinib tablets in combination with nivolumab as first-line treatment of advanced renal cell carcinoma in adults |
Ongoing |
Cabozantinib |
4 |
CLIN-60000 |
King Abdulaziz Medical City NG (Riyadh) |
| A Randomized, Double-blind, Multicenter Study to Determine the Effect of Triheptanoin Compared with Even-chain, Medium-chain Triglycerides (MCT) on Major Clinical Events (MCEs) in Pediatric Patients with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) |
Ongoing |
UX007/triheptanoin, Medium-chain Triglycerides (MCT),Dextrose. Monosaccharide. Blood Glucose-Elevating Agents. |
3 |
UX007-CL30 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A non-interventional, multinational,observational study with isatuximabin patients with relapsed and/orrefractory multiple myeloma (RRMM) |
Ongoing |
SARCLISA® ( isatuximab - irfc ) |
4 |
OBS16577 |
Mouwasat Hospital (Dammam),King Faisal Specialist Hospital and Research Center (Jeddah),King Abdulaziz Medical City NG (Jeddah),King Abdulaziz Medical City NG (Riyadh) |
| A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum |
Ongoing |
Hydrocortisone Acetate 90 mg |
3 |
CHS1221 |
King Abdulaziz Medical City NG (Jeddah),King Abdulaziz University Hospital (Jeddah),King Fahad Medical City (Riyadh) |
| International collaborative treatment protocol for infants under one year with KMT2Arearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia (Interfant-21) |
Ongoing |
BLINATUMOMAB |
3 |
SCT22R/016/12 |
King Abdulaziz Medical City NG (Riyadh),King Abdulaziz Medical City NG (Jeddah) |
| A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS LENVATINIB OR SORAFENIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZUMAB |
Rejected |
ATEZOLIZUMAB, SORAFENIB |
3 |
MO42541 |
King Abdulaziz Medical City NG (Riyadh) |
| An Open label, Single Center, prospective interventional, phase II clinical trial to evaluate the Efficacy and Safety of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine(BV-AVD) combination escalation in advanced stage classical Hodgkin lymphoma patients who did not achieve interim Positron Emission Tomography (PET2) negativity (defined as Deauville score 3 or less) after 2 cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) |
Rejected |
BRENTUXIMAB VEDOTIN, DACARBAZINE, VINBLASTINE, DOXORUBICIN HYDROCHLORIDE |
2 |
1 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
